Premium
Biweekly dose‐dense gemcitabine–oxaliplatin and dexamethasone for relapsed/refractory aggressive non‐Hodgkin lymphoma: A multicenter, single‐arm, phase II trial
Author(s) -
Jo JaeCheol,
Baek Jin Ho,
Lee JeHwan,
Joo YoungDon,
Bae SungHwa,
Lee JungLim,
Lee JungHee,
Kim DaeYoung,
Lee WonSik,
Ryoo Hun Mo,
Choi Yunsuk,
Kim Hawk,
Lee KyooHyung
Publication year - 2016
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12462
Subject(s) - medicine , gemcitabine , oxaliplatin , regimen , neutropenia , chemotherapy , gastroenterology , dexamethasone , refractory (planetary science) , phases of clinical research , lymphoma , chemotherapy regimen , surgery , oncology , cancer , physics , colorectal cancer , astrobiology
Aim We performed a phase II study to evaluate the efficacy of combination chemotherapy consisting of gemcitabine, dexamethasone and oxaliplatin (GemDOx) as a biweekly regimen and salvage therapy in patients with relapsed or refractory aggressive non‐Hodgkin lymphoma (NHL). Methods Gemcitabine (1000 mg/m 2 ) and oxaliplatin (85 mg/m 2 ) were administered intravenously on days 1 and 15, and dexamethasone (40 mg) was administered orally on days 1–4. Results Twenty‐nine patients were enrolled, and most patients had diffuse large B‐cell lymphoma ( n = 18). The median age of the patients and median prior number of chemotherapy cycles were 53 (range, 26–74) years and 1 (range, 1–4) cycle, respectively. Only 17 (58.6%) and 9 (31.0%) patients completed two or more and four or more cycles, respectively, and the median number of received cycles was two (range, 1–8). Overall response rates were 27.6% (complete response in 13.8%) among intent‐to‐treat patients and 47.1% (complete response in 23.5%) among patients who had received at least two GemDOx cycles. Median progression‐free survival and median overall survival were 3.9 and 20.5 months, respectively. The most‐frequent grade 3 or 4 toxicity was neutropenia (22.9%), and no grade 3 or 4 peripheral neurotoxicity was noted. Conclusion GemDOx chemotherapy, therefore, showed modest activity against relapsed or refractory aggressive NHL, although toxicities were acceptable.